My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novavax, Inc. - Common Stock (NQ:NVAX)

6.950 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

65 66 Next >

Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated ↗

May 08, 2025

The company raised its full-year revenue guidance to between $975 million and $1.025 billion, up from its previous guidance of between $300 million and $350 million.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 08, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Uncovering Potential: Novavax's Earnings Preview ↗

May 07, 2025

Via Benzinga

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 06, 2025

Via Benzinga

Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline ↗

April 29, 2025

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting...

Via Benzinga

Topics Government

Novavax Tops Weekly Retail Buzz Spike Amid FDA Trial Drama, COVID-19 Vaccine Approval Hopes ↗

April 27, 2025

Optimism was tempered by a Wall Street Journal report on Friday, which said federal regulators had asked Novavax to conduct another randomized clinical trial of its COVID-19 vaccine.

Via Stocktwits

Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back ↗

April 26, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps ↗

April 23, 2025

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision.

Via Benzinga

Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday ↗

April 23, 2025

Via Benzinga

Novavax Signals Chances Of FDA Approval For Its COVID-19 Vaccine: But Retail Sentiment Wavers ↗

April 23, 2025

The company announced on Wednesday that it had received formal communication from the FDA in the form of an information request for a “postmarketing commitment” to generate additional clinical data.

Via Stocktwits

Topics Government

Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study ↗

April 15, 2025

Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study.

Via Benzinga

Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling ↗

April 10, 2025

Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 10, 2025

Via Benzinga

These stocks are gapping in today's session ↗

April 10, 2025

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

April 08, 2025

Via The Motley Fool

Topics Cannabis Government Law Enforcement

Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst ↗

April 03, 2025

Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.

Via Benzinga

Topics World Trade

Novavax Vaccine Approval From FDA In Limbo, Says Report – But Retail Is Hopeful ↗

April 02, 2025

Though the FDA was set to give full approval to the vaccine, senior leaders at the agency have now said that the company’s application needs more data and is unlikely to be approved soon, The Wall...

Via Stocktwits

FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine ↗

April 02, 2025

Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.

Via Benzinga

Moderna, Novavax Shares Are Tumbling Monday: What's Going On? ↗

March 31, 2025

Vaccine stocks are trading lower Monday following a shakeup at the U.S. Food and Drug Administration.

Via Benzinga

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗

March 31, 2025

Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.

Via Investor's Business Daily

Moderna, Novavax Shares Are Sliding Wednesday: What's Going On? ↗

March 26, 2025

Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.

Via Benzinga

Topics Government

2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying ↗

March 15, 2025

Via The Motley Fool

Nvidia, Tesla Lead Tech Stock Rebound: What's Driving Markets Friday? ↗

February 28, 2025

Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQ:NVDA) up 1.37% and Tesla, Inc. (NASDAQ:TSLA)

Via Benzinga

1 Biotech Stock to Buy in 2025, and 1 to Avoid ↗

February 28, 2025

Via The Motley Fool

Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership ↗

February 27, 2025

The company expects to generate $300 million to $350 million in adjusted licensing, royalties, and other revenue in 2025.

Via Stocktwits

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value ↗

February 27, 2025

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue.

Via Benzinga

Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples ↗

February 27, 2025

Kennedy, a longtime vaccine skeptic, now oversees HHS decisions that could impact vaccine makers, making his leadership a wild card for Novavax.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

65 66 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.